A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer

Condition:   Breast Cancer Interventions:   Drug: Ipatasertib;   Drug: Placebo;   Drug: Palbociclib;   Drug: Fulvestrant Sponsor:   Hoffmann-La Roche Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials